cladribine,lintuzumab,Cytarabine,Filgastrim,Mitoxantrone
merck,seagen,amgen
['determination', 'rp2 ', 'equate', 'leusm', 'aml,(-streamline),(-seamless),(-kamloops),(-latamleaders)', 'fil,veral,12', 'lintuzumab', 'aml,(-streamline),(-seamless),(-kamloops),(-dreamlike)', 'leukemia', 'emergent ']
congress | #ash22
sameem abedin , shows 53% 1 year os and 32% at 2 years with salvage lintuzumab-ac225 (actimab-a) plus clag-m in phase 1 trial in patients with r/r aml, with 64% progressing to allo-hsct.
#leusm #medicalcongress 
The AML Hub is an evidence-based online resource on Acute Myeloid Leukemia (AML), for academic researchers and treating clinicians. #leusm